Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping

SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. This virtual symposium provides a unique platform for researchers to present cutting-edge findings and share insights into emerging applications of OGM technology.

Join leading scientists from around the world as they highlight breakthroughs in OGM from February 23-26, 2026. The four-day event will feature presentations from over 30 researchers across North America, Europe, and Asia, covering research applications in hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy. The virtual program includes scientific presentations, interactive panel discussions with Q&A, and a virtual poster hall.

"At Bionano, we are transforming the way the world sees the genome," said Erik Holmlin, president and chief executive officer of Bionano. "Our Symposium brings together the global OGM community to share real-world experiences and demonstrate how OGM can reveal genomic complexity that is difficult to detect with conventional technologies. The 2026 program highlights the expanding role of OGM in oncology research, constitutional genetics, and bioprocessing.”

“We provide the technology, and scientists continue to redefine what’s possible with it,” said Alka Chaubey, PhD, FACMG, chief medical officer at Bionano. “The 2026 Symposium will showcase how researchers worldwide are advancing genome analysis through innovative applications of OGM and establishing it as a cornerstone tool for modern cytogenetic and genome analysis.”

Each session will begin at 7:00 AM PST and last approximately three hours, opening with a technology introduction and brief remarks from Dr. Chaubey and followed by presentations from invited external speakers, a live panel discussion and Q&A. Attendees can also explore scientific posters within the virtual platform throughout the event.

Symposium 2026 Overview:

• Monday, February 23: Advancements in Hematologic Malignancies with OGM
  From leukemias to lymphomas and myelomas, hear how cytogenetic labs and key opinion leaders (KOLs) worldwide are implementing OGM across multiple research applications. Experts will share insights on workflow performance compared to traditional cytogenetic and molecular methods, highlighting OGM’s precision, sensitivity, and discuss how OGM helps identify pathogenic structural variants and streamlines laboratory workflows.
  
  
  • Ravindra Kolhe, MD, PhD, FACP – Augusta University, USA
  • Wahab A. Khan, PhD, FACMG – Dartmouth-Hitchcock Medical Center, USA
  • Amber Verhasselt - KU Leuven, Belgium
  • Klaudia Starosz- Medical University of Lodz, Poland
  • Gokce A. Toruner, MD, PhD, FACMG – The University of Texas MD Anderson Cancer Center, USA
  • Elly De Vlieghere, PhD, MSc - AZ Sint-Jan Brugge, Belgium
  • Anna Maria Puiggros Metje - Hospital del Mar, Spain
  • Rashmi Kanagal Shamanna, MD - The University of Texas MD Anderson Cancer Center, USA
    
    

• Tuesday, February 24: New Frontiers in Oncology Research and Bioprocessing Applications
  Discover how OGM can reveal pathogenic and driver structural variants in challenging indications, including multiple myeloma, lymphomas, and solid tumors. Learn how OGM is also being used as a genome integrity quality control tool for cell and gene therapy applications.
  
  
  • Hippolyte Guerineau, PharmD - Centre Hospitalier de Versailles, France
  • Agnes Daudignon, PhD - CHU de Lille, France
  • Ying S. Zou, MD, PhD, FACMG - Johns Hopkins University School of Medicine, USA
  • Alejandro Berenguer Rubio, MD - Instituto de Investigación Sanitaria La Fe (IIS La Fe), Spain
  • Darren "Ben" Finlay, PhD - Sanford Burnham Prebys Medical Discovery Institute, USA
  • James Haldane – iPSC Platform bit.bio, UK
  • Annelise Bennaceur Griscelli – CiTHERA- Center for iPS Cell Therapies, France
  • Marc-Henri Stern, MD PhD - Institut Curie, France
    
  • Phillip D. Michaels, MD - Brigham and Women’s Hospital and Harvard University, USA
  • Adrian Dubuc, PhD, FACMG - Roswell Park Comprehensive Cancer Center, USA
    
    

• Wednesday, February 25: OGM Making Its Mark in Constitutional Genetic Disorder Research
  Speakers will share experiences using OGM to uncover structural variants in rare and unresolved genetic disorders, developmental disorders, and reproductive conditions, including recurrent pregnancy loss.
  
  
  • Yassmine Akkari, PhD, FACMG - Nationwide Children's Hospital, USA
  • Debopriya Chakraborty - Dartmouth-Hitchcock Medical Center, USA
  • Walaa Darwiche, PhD - CHU Amiens – Picardie, France
  • Li Fu, MD - Yokohama City University Graduate School of Medicine, Japan
  • Laila El Khattabi, PhD, PharmD - Sorbonne University APHP Hospitals and Paris Brain Institute, France
  • Karthik Bharadwaj Tallapaka, MD, DrNB - Centre for Cellular and Molecular Biology, India
  • Bruna Burssed, MSc - Universidade Federal de São Paulo (UNIFESP), Brazil and Radboud University Medical Center, The Netherlands
  • Mehmet Burak Mutlu, MD - Detagen Genetic Diseases Diagnosis and Evaluation Center, Turkey
  • Nikhil Sahajpal, PhD, FACMG - Greenwood Genetic Center, USA
    
    

• Thursday, February 26: Genome Analysis Landscape with Bionano Products: Ionic®, Saphyr®, and Stratys™ systems, and VIA™ software
  Learn directly from customers about Bionano tools, including Ionic, Saphyr, and Stratys systems, and VIA software. KOLs from the US, Canada, and Netherlands will discuss FFPE DNA isolation for downstream NGS, semi-automated ultra-high molecular DNA isolation for OGM, high-throughput Stratys applications, and a live demo of VIA software for analysis of hematologic malignancies.
  
  
  • Alex Hoischen, PhD - Radboud University Medical Center, The Netherlands
  • Chantal Courtemanche, PhD - CHU de Québec, Canada
  • Vineet Bafna, PhD –University of California San Diego, USA
  • Brandon M. Shaw, PhD, FACMG, DABMGG –Henry Ford Health System, USA
  • Elizabeth McCready, PhD, PCCMG - Hamilton Health Sciences Center, Canada
  • Eddy N De Boer - University Medical Centre Groningen, The Netherlands
  • Arjan Buijs - University Medical Centre Groningen, The Netherlands
  • Adam C. Smith, PhD, FCCMG, FACMG, erCLG – Labcorp, USA
    
    

Registration is free and open to all. Secure your spot today at: www.bionano.com/symposium-2026/

Showcase your work to the global OGM community! Submit your poster here: https://bionanosymposium2026.vfairs.com/en/poster-submission

About Bionano Genomics

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things; the ability and utility of OGM for research applications in hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy; the ability and utility of OGM as a genomic analysis tool in the applications presented in Symposium 2026; the ability and utility of OGM to reveal genomic complexity that is difficult to detect with conventional technologies; the impact of Symposium 2026 to advance our commercial goals including market development and OGM adoption; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; and any other statements that are not of historical fact. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM to be useful for research applications in hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy; the failure OGM to be a useful genomic analysis tool in the applications presented in Symposium 2026; the failure of OGM to reveal genomic complexity that is difficult to detect with conventional technologies; the failure of Symposium 2026 to advance our commercial goals including market development and OGM adoption; future research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies that differ or contradict the research, presentations and publications referenced in this press release and at Symposium 2026; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties including those described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com